Network Meta-Analysis Ranks Best Biologics for Chronic Urticaria Treatment
A landmark 93-study network meta-analysis identifies omalizumab and remibrutinib as top treatments for antihistamine-refractory chronic urticaria.
Summary
A comprehensive systematic review and Bayesian network meta-analysis evaluated 42 systemic treatments for chronic urticaria across 93 studies involving over 11,000 patients. Standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib emerged as the most effective options for improving itch, wheals, angioedema, and quality of life, with high certainty evidence. Dupilumab improved urticaria activity but showed uncertain effects on angioedema and quality of life. Cyclosporine demonstrated strong efficacy but carried the highest adverse event burden. Conventional immunosuppressants like azathioprine and hydroxychloroquine showed possible benefit but with uncertain evidence. Agents including benralizumab and tezepelumab appeared no better than placebo. Results were consistent across age groups and disease severity.
Detailed Summary
Chronic urticaria — persistent hives, angioedema, or both lasting six or more weeks — affects millions worldwide and significantly impairs quality of life. While antihistamines are first-line therapy, a substantial proportion of patients remain refractory and require systemic treatments. Until now, head-to-head comparisons across the full landscape of available biologics and immunomodulators were lacking, leaving clinicians without clear guidance on sequencing or selecting therapies.
This study, commissioned to update the AAAAI/ACAAI Joint Task Force Practice Parameters, conducted a rigorous systematic review and Bayesian network meta-analysis of 93 studies (83 randomized trials, 10 nonrandomized studies) encompassing 11,398 participants and 42 interventions. Databases searched included Medline, Embase, Cochrane Central, and multiple Chinese biomedical databases through February 2025. Outcomes assessed included urticaria activity scores, angioedema activity, health-related quality of life, and adverse events, with certainty rated using the GRADE framework.
With high certainty, standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib — a BTK inhibitor — ranked among the most effective treatments across multiple patient-important outcomes. Remibrutinib's safety profile, however, remains less established. Dupilumab (IL-4/IL-13 blockade) improved itch and wheal scores but its effects on angioedema and quality of life remain uncertain. Cyclosporine showed strong efficacy for urticaria activity but was associated with the highest frequency of adverse events among evaluated agents. Lower omalizumab doses offered intermediate benefit with favorable safety. Several conventional immunosuppressants showed possible benefit with uncertain evidence, while benralizumab, quilizumab, and tezepelumab did not outperform placebo.
For clinicians managing antihistamine-refractory chronic urticaria, these findings provide the most comprehensive comparative evidence to date. Omalizumab remains the best-supported biologic, while remibrutinib represents a promising emerging option pending longer-term safety data.
Caveats include reliance on indirect comparisons inherent to network meta-analysis, limited pediatric data, and short study durations that may not capture long-term safety signals, particularly for newer agents like remibrutinib.
Key Findings
- Standard-dose omalizumab (300 mg/4 weeks) is among the most effective and safest treatments for chronic urticaria with high certainty.
- Remibrutinib (BTK inhibitor) matches omalizumab in efficacy but has a less established long-term safety profile.
- Dupilumab improves itch and wheals but shows uncertain benefit for angioedema and quality of life.
- Cyclosporine is highly effective but carries the greatest adverse event burden among evaluated agents.
- Benralizumab, quilizumab, and tezepelumab showed no significant benefit over placebo.
Methodology
Bayesian random-effects network meta-analysis of 93 studies (11,398 participants) evaluating 42 interventions, with databases searched through February 2025. Certainty of evidence was assessed using the GRADE framework, and risk of bias was evaluated by paired independent reviewers.
Study Limitations
Network meta-analysis relies on indirect treatment comparisons, which may introduce uncertainty not present in head-to-head trials. Most studies enrolled adults and adolescents, limiting generalizability to young children. Study durations were generally short, potentially underestimating long-term safety risks, especially for newer agents like remibrutinib.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.